Hexagon Bio Stock
HealthTechLooking to sell Hexagon Bio stock or options?
Hexagon Bio has developed a synthetic biology platform that leverages data science to explore genomes for small molecule inhibitors targeting specific proteins. This platform integrates genomics, synthetic biology, and automation to uncover evolutionarily refined compounds and their protein targets directly from fungal genomes. By tapping into the global metagenome, Hexagon Bio aims to identify new medicinal compounds, facilitating the development of innovative treatments to enhance patient care.
SoftBank Investment Advisers, Nextech Invest, Trancos Venture, LeFrak, Luma Bio-IT Management, Sherpalo Ventures, Casdin Capital, ATEL Capital Group, CPP Investments, bpd partners, Julia Hong, The Column Group, 8VC, Two Sigma Ventures.
Collective explained in 2 minutes
Learn how Collective's solutions enable you to manage your risk and maximize your wealth
Our available services for this company
Management Team
Board Members
Hexagon Bio’s stock FAQs
Hexagon Bio is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Hexagon Bio stock. Depending on Hexagon Bio’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Hexagon Bio stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Hexagon Bio stock in two ways. First, Hexagon Bio employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Hexagon Bio stock. Note that all transactions in Hexagon Bio shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Hexagon Bio stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Hexagon Bio stock. Typically, shares of private companies like Hexagon Bio are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Sep 2022, Hexagon Bio is reported to have closed an equity financing in which the investors valued the company at $338M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Hexagon Bio shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Hexagon Bio is not currently publicly traded, it does not have a ticker symbol.
Hexagon Bio has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Hexagon Bio is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Hexagon Bio shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
